Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.38 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | CDA | P32320 | 6/20 | 0.34 |
| ▸ | OGA | O60502 | 3/20 | 0.34 |
| ▸ | PYGB | P11216 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL967650 | 1.00 | LGALS1 (0.38) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL15603335 | 0.86 | CDA (0.42) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL3359938 | 0.86 | CDA (0.42) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL13697136 | 0.86 | CDA (0.42) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL14501426 | 0.86 | CDA (0.42) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL14416499 | 0.86 | CDA (0.42) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL1031687 | 0.86 | CDA (0.42) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL1031685 | 0.86 | CDA (0.42) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL15603391 | 0.86 | CDA (0.42) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL15603406 | 0.86 | CDA (0.42) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130134-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-27 | — | — | US | disclosed |
| US-9149489-B2 | Inhibitors of glycolysis useful in the treatment of brain tumors | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2015-10-06 | — | — | US | disclosed |
| US-9149489-B2 | Inhibitors of glycolysis useful in the treatment of brain tumors | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2015-10-06 | — | — | US | disclosed |
| US-20120276108-A1 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | INTERTECH BIO (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120276108-A1 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | INTERTECH BIO (US) | 2012-11-01 | — | — | US | disclosed |
| WO-2012097052-A2 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | INTERTECH BIO, LLC (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20110003758-A1 | Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-06 | — | — | US | disclosed |
| US-20110003758-A1 | Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003758-A1 | Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors | PDK2, G6PD, PCK2 | LGALS1 1153/4885LGALS3 1827/4885LGALS9 2366/4885 |
| US-20230130134-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | G6PD, FBP1, ALDOA | LGALS1 232/4885LGALS3 292/4885LGALS9 490/4885 |
| US-20120276108-A1 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | IGF1R, IRS1, IGFBP1 | LGALS1 109/4885LGALS3 409/4885LGALS9 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.